#ezh2 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #ezh2, aggregated by home.social.
-
EZH2 (PRC2) trimethylates H3K27 → PRC1 recruitment → chromatin compaction → transcriptional silencing.
Elegant at the mechanistic level. Consequential at the organismal level — elevated EZH2 activity shortens lifespan in model organisms, likely via progressive silencing of stress-response loci.
The SET domain may be one of the most underrated targets in aging biology.
#EZH2 #PRC2 #Epigenetics #AgingBiology #H3K27me3 #ChromatinRemodeling #Longevity
-
Un enzima chiamato EZH2 decide quali cellule tumorali diventeranno metastasi. Non modifica il DNA direttamente: lo avvolge, silenziando i geni che mantengono l'ordine nella divisione cellulare. Il 5% delle cellule del tumore triplo negativo usa questo meccanismo per viaggiare. La buona notizia? Esistono farmaci che bloccano EZH2 e sono già stati approvati.
https://www.futuroprossimo.it/2025/10/ezh2-trovato-linterruttore-delle-metastasi/
-
Seung Kim, Frederick Dick et al show that resting #Bcells are uniquely sensitive to #EZH2 #polycomb complex inhibition, which activates expression of repetitive genomic elements and subsequent #innateimmune receptor signaling in a form of viral mimicry
-
Seung Kim, Frederick Dick et al show that resting #Bcells are uniquely sensitive to #EZH2 #polycomb complex inhibition, which activates expression of repetitive genomic elements and subsequent #innateimmune receptor signaling in a form of viral mimicry
-
Seung Kim, Frederick Dick et al show that resting #Bcells are uniquely sensitive to #EZH2 #polycomb complex inhibition, which activates expression of repetitive genomic elements and subsequent #innateimmune receptor signaling in a form of viral mimicry
-
"These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential #EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with #neuroblastoma".
An article that I had missed, by Mabe et al., linking #mesenchymal #tumour cell state, #GD2 expression, #ST8SIA1 expression, and #immunotherapy #TherapyResistance.
https://www.nature.com/articles/s43018-022-00405-x
Sadly, not open access.
-
"These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential #EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with #neuroblastoma".
An article that I had missed, by Mabe et al., linking #mesenchymal #tumour cell state, #GD2 expression, #ST8SIA1 expression, and #immunotherapy #TherapyResistance.
https://www.nature.com/articles/s43018-022-00405-x
Sadly, not open access.
-
"These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential #EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with #neuroblastoma".
An article that I had missed, by Mabe et al., linking #mesenchymal #tumour cell state, #GD2 expression, #ST8SIA1 expression, and #immunotherapy #TherapyResistance.
https://www.nature.com/articles/s43018-022-00405-x
Sadly, not open access.
-
"These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential #EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with #neuroblastoma".
An article that I had missed, by Mabe et al., linking #mesenchymal #tumour cell state, #GD2 expression, #ST8SIA1 expression, and #immunotherapy #TherapyResistance.
https://www.nature.com/articles/s43018-022-00405-x
Sadly, not open access.
-
New discoveries about #Polycomb #EZH2 function in #MultipleMyeloma and a therapeutic avenue here:
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023). https://doi.org/10.1038/s41388-023-02618-5 -
New discoveries about #Polycomb #EZH2 function in #MultipleMyeloma and a therapeutic avenue here:
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023). https://doi.org/10.1038/s41388-023-02618-5 -
New discoveries about #Polycomb #EZH2 function in #MultipleMyeloma and a therapeutic avenue here:
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023). https://doi.org/10.1038/s41388-023-02618-5